the aid library

Filter

867

Maintaining essential health services: operational guidance for the COVID-19 context
recommended

World Health Organization WHO (2020) C_WHO

1 June 2020 Countries around the world are facing the challenge of increased demand for care of people with COVID-19, compounded by fear, misinformation and limitations on movement that disrupt the delivery of health care for all conditions. Maintaining essential health services: operational guidan ... more

Monitoring and restricting digital marketing of unhealthy products to children and adolescents

World Health OrganizationEurope (2019) C_WHO

The WHO European Office for the Prevention and Control of Noncommunicable Diseases organized an expert meeting on monitoring of digital marketing of unhealthy products to children and adolescents in June 2018. Based on that meeting, this report aims to provide a tool to support Member States in moni ... more

ИНИЦИАТИВА SAFER СДЕЛАТЬ ЕВРОПЕЙСКИЙ РЕГИОН ВОЗ БОЛЕЕ БЕЗОПАСНЫМ

World Health Organization WHO, Regional Office of Europe (2021) C_WHO

УСПЕХИ В РЕАЛИЗАЦИИ ПОЛИТИКИ В ОТНОШЕНИИ КОНТРОЛЯ НАД АЛКОГОЛЬНОЙ ПРОДУКЦИЕЙ, 2010–2019 ГГ A detailed overview is provided of the implementation of alcohol policies described in the 10 action areas of the European Action Plan ... more

Standards for Prosthetics and Orthotics. Part 1: Standards

World Health Organization (WHO) (2017) C_WHO

WHO, in partnership with the International Society for Prosthetics and Orthotics (ISPO) and the United States Agency for International Development (USAID), has published global standards for prosthetics and orthotics. Its aim is to ensure that prosthetics and orthotics services are people-centred an ... more

WHO framework for meaningful engagement of people living with noncommunicable diseases, and mental health and neurological conditions

World Health Organisation (WHO) (2023) C_WHO

The overall objective of the framework is to support WHO and Members States in meaningful engagement of people living with NCDs, and mental health and neurological conditions to co-create and enhance related policies, programmes and services. This framework will contribute to advancing understanding ... more

Dietary salt intake survey in the Republic of Moldova, 2016

World Health OrganizationEurope (2018) C_WHO

High salt consumption is an important determinant of high blood pressure and reducing it would improve health outcomes by lowering cardiovascular disease and therefore death rates. Reducing salt intake has been identified as one of the most effective public health measures and is one of the leading ... more

Rwanda Fourth Health Sector Strategic Plan (July 2018-June 2024)
recommended

Ministry of Health, Rwanda (2018) C2

Rwanda’s fourth health sector strategic plan (HSSP4) is meant to provide the health sector with a Strategic Plan that will highlight its commitments and priorities for the coming 6 years. It will be fully integrated in the overall economic development plan of the Government. HSSP4 will fulfill the ... more

Accelerating access to hepatitis C diagnostics and treatment

World Health Organization WHO (2021) C2

Overcoming barriers in low- and middle-income countries For the first time, this year’s report includes information on hepatitis C diagnostics. With a focus on selected countries with diverse HCV epidemics, the report provides updates on the various dimensions of access to HCV diagnostics and pha ... more

Atlas of African Health Statistics 2022: Health situation analysis of the WHO African Region

World Health Organisation (WHO) (2022) C_WHO

Atlas of African Health Statistics 2022: Health situation analysis of the WHO African Region Since 2019, we have been implementing Phase 2 of the regional Transformation Agenda, which informs and aligns with the global WHO Transformation, to ensure WHO is accountable, driven by re- sults and provid ... more

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for ... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Prevention of Cardiovascular Disease: Guidelines for assessment and management of cardiovascular risk

World Health Organization WHO (2007) C_WHO

Cardiovascular disease is a major cause of disability and premature death throughout the world, and contributes substantially to the escalating costs of health care. The underlying pathology is atherosclerosis, which develops over many years and is usually advanced by the time symptoms occur, genera ... more

Health Sector Strategic Plan II (2017-2022) Malawi

The Government of Malawi (2017) C1

Integrating palliative care and symptom relief into paediatrics: a WHO guide for health-care planners, implementers and managers

World Health Organization WHO (2018) C_WHO

People younger than 20 years comprise 35% of the global population and 40% of the global population of least-developed nations. The number of children - neonates, infants, children, and adolescents up to 19 years of age - who need pediatric palliative care (PPC) each year may be as high as 21 millio ... more

Democratic Republic of the Congo Taxometry

World Health Organization; Regional Office for Africa (2010) C_WHO

Use of cryotherapy for cervical intraepithelial neoplasia

World Health Organization WHO (2011) C_WHO

Standard treatment guidelines medicine (Respiratory Diseases) India

Ministry of Health & Family Welfare, India (2020) C1

Accessed Febr. 6, 2020

Zambia – United Nations Sustainable Development Partnership Framework ( 2016 - 2021)

Government of Zambia and the United Nations in Zambia (2016) C1

PEPFAR Zambia Country Operational Plan (COP) 2018 Strategic Direction Summary

PEPFAR (2018) C2

Global atlas of palliative care at the end of life

World Palliative Care Alliance; WHO (2020) C_WHO

The second edition of the WHPCA Global Atlas of Palliative Care was launched during World Hospice & Palliative Care Day 10 October. The Atlas is an update of the original WHPCA/WHO Global Atlas of Palliative care at the end of life published in 2014. It is full of useful facts and figures to support ... more

Health Sector Supply Chain Strategy and Implementation Plan (2015-2017)

Ministry of Health, Zambia (2015) C1